<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Summary of periprocedural management of anticoagulants and antiplatelet medications for interventional pain procedures</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Summary of periprocedural management of anticoagulants and antiplatelet medications for interventional pain procedures</h1>
<div class="graphic"><div class="figure"><div class="ttl">Summary of periprocedural management of anticoagulants and antiplatelet medications for interventional pain procedures</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Drug</td> <td class="subtitle1" colspan="3">When to stop</td> <td class="subtitle1" rowspan="2">When to restart</td> </tr> <tr> <td class="subtitle2">High-risk procedures</td> <td class="subtitle2">Intermediate-risk procedures</td> <td class="subtitle2">Low-risk procedures</td> </tr> <tr class="divider_bottom"> <td>ASA and ASA combinations</td> <td> <p>Primary prophylaxis: 6 days</p> Secondary prophylaxis: Shared assessment and risk stratification</td> <td>Shared assessment and risk stratification*<sup>¶</sup></td> <td>No</td> <td>24 hours</td> </tr> <tr class="divider_bottom"> <td><strong>NSAIDs</strong></td> <td>5 half-lives</td> <td>No<sup>Δ</sup></td> <td>No</td> <td>24 hours</td> </tr> <tr> <td class="indent1">Diclofenac</td> <td>1 day</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Ketorolac</td> <td>1 day</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Ibuprofen</td> <td>1 day</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Etodolac</td> <td>2 days</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Indomethacin</td> <td>2 days</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Naproxen</td> <td>4 days</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Meloxicam</td> <td>4 days</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Nabumetone</td> <td>6 days</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Oxaprozin</td> <td>10 days</td> <td> </td> <td> </td> <td> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Piroxicam</td> <td>10 days</td> <td> </td> <td> </td> <td> </td> </tr> <tr class="divider_bottom"> <td><strong>Phosphodiesterase inhibitors</strong></td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Cilostazol</td> <td>2 days</td> <td>No</td> <td>No</td> <td>24 hours</td> </tr> <tr> <td class="indent1">Dipyridamole</td> <td>2 days</td> <td>No</td> <td>No</td> <td> </td> </tr> <tr class="divider_bottom"> <td class="indent1">ASA combinations</td> <td>Follow ASA recommendations</td> <td>Shared assessment and risk stratification*</td> <td> </td> <td> </td> </tr> <tr class="divider_bottom"> <td><strong>Anticoagulants</strong></td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Coumadin</td> <td>5 days, normal INR</td> <td>5 days, normal INR</td> <td>No; shared assessment and risk stratification*</td> <td>6 hours</td> </tr> <tr> <td class="indent1">Acenocoumarol</td> <td>3 days, normal INR</td> <td>3 days, normal INR</td> <td>No; shared assessment and risk stratification*</td> <td>24 hours</td> </tr> <tr> <td class="indent1">IV heparin</td> <td>6 hours</td> <td>6 hours</td> <td>6 hours</td> <td>2 hours<sup>◊</sup></td> </tr> <tr> <td class="indent1">Subcutaneous heparin, BID, and TID</td> <td>24 hours</td> <td>6 hours</td> <td>6 hours</td> <td> <p>2 hours (low-/intermediate-risk procedures)</p> 6 hours (high-risk procedures</td> </tr> <tr> <td class="indent1">LMWH: Enoxaparin (prophylactic)</td> <td>12 hours</td> <td>12 hours</td> <td>12 hours</td> <td> <p>4 hours (low-risk procedures)</p> 12 to 24 hours (medium-/high-risk pain procedures)</td> </tr> <tr> <td class="indent1">LMWH: Enoxaparin (therapeutic)</td> <td>24 hours</td> <td>24 hours</td> <td>24 hours</td> <td> <p>4 hours (low-risk procedures)</p> 12 to 24 hours (intermediate-/high-risk pain procedures)</td> </tr> <tr class="divider_bottom"> <td class="indent1">LMWH: Dalteparin</td> <td>24 hours</td> <td>24 hours</td> <td>24 hours</td> <td> <p>4 hours (low-risk procedures)</p> 12 to 24 hours (intermediate-/high-risk pain procedures)</td> </tr> <tr class="divider_bottom"> <td><strong>Fibrinolytic agents</strong></td> <td>48 hours</td> <td>48 hours</td> <td>48 hours</td> <td>N/A<sup>§</sup></td> </tr> <tr class="divider_bottom"> <td class="indent1">Fondaparinux</td> <td>4 days</td> <td>4 days</td> <td>Shared assessment and risk stratification</td> <td> <p>6 hours (low-/intermediate-risk procedures)</p> 24 hours (high-risk procedures)</td> </tr> <tr class="divider_bottom"> <td><strong>P2Y12 inhibitors</strong></td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Clopidogrel</td> <td>7 days</td> <td>7 days</td> <td>No; shared assessment and risk stratification</td> <td>12 to 24 hours*</td> </tr> <tr> <td class="indent1">Prasugrel</td> <td>7 to 10 days</td> <td>7 to 10 days</td> <td>No; shared assessment and risk stratification</td> <td>24 hours</td> </tr> <tr> <td class="indent1">Ticagrelor</td> <td>5 days</td> <td>5 days</td> <td>No; shared assessment and risk stratification</td> <td>24 hours</td> </tr> <tr class="divider_bottom"> <td class="indent1">Cangrelor</td> <td>3 hours</td> <td>3 hours</td> <td>Shared assessment and risk stratification</td> <td>24 hours</td> </tr> <tr class="divider_bottom"> <td><strong>NOACs</strong></td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Dabigatran</td> <td> <p>4 days</p> 5 to 6 days (impaired renal function)</td> <td> <p>4 days</p> 5 to 6 days (impaired renal function)</td> <td>Shared assessment and risk stratification*</td> <td>24 hours</td> </tr> <tr> <td class="indent1">Rivaroxaban</td> <td>3 days</td> <td>3 days</td> <td>Shared assessment and risk stratification*</td> <td>24 hours</td> </tr> <tr> <td class="indent1">Apixaban</td> <td>3 days</td> <td>3 days</td> <td>Shared assessment and risk stratification*</td> <td>24 hours</td> </tr> <tr class="divider_bottom"> <td class="indent1">Edoxaban</td> <td>3 days</td> <td>3 days</td> <td>Shared assessment and risk stratification*</td> <td>24 hours</td> </tr> <tr class="divider_bottom"> <td><strong>GP IIb/IIIa inhibitors</strong></td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Abciximab</td> <td>2 to 5 days</td> <td>2 to 5 days</td> <td>2 to 5 days</td> <td>8 to 12 hours</td> </tr> <tr> <td class="indent1">Eptifibatide</td> <td>8 to 24 hours</td> <td>8 to 24 hours</td> <td>8 to 24 hours</td> <td>8 to 12 hours</td> </tr> <tr class="divider_bottom"> <td class="indent1">Tirofiban</td> <td>8 to 24 hours</td> <td>8 to 24 hours</td> <td>8 to 24 hours</td> <td>8 to 12 hours</td> </tr> <tr> <td><strong>Antidepressants and SRIs</strong></td> <td>Individualized<sup>¥</sup></td> <td>No</td> <td>No</td> <td>Individualized<sup>¥</sup></td> </tr> </tbody></table></div><div class="graphic_footnotes">ASA: aspirin; INR: international normalized ratio; IV: intravenous; BID: two times per day; TID: three times per day; LMWH: low-molecular-weight heparin; N/A: not applicable; NOACS: novel oral anticoagulants; GP: glycoprotein; SRIs: serotonin reuptake inhibitors.<br/>* Refer to detailed text in the corresponding section of the source article.<br/>¶ Consideration should be given to the discontinuation of ASA for certain intermediate-risk procedures including interlaminar cervical ESIs and stellate ganglion blocks where specific anatomical configurations may increase the risk and consequences of procedural bleeding.<br/>Δ Consideration should be given to the discontinuation of NSAIDs for certain intermediate-risk procedures including interlaminar cervical ESIs and stellate ganglion blocks where specific anatomical configurations may increase the risk and consequences of procedural bleeding (refer to the section entitled "Anatomical Considerations for the Development of a Hematoma in Spinal and Non‐spinal Areas" in the source article).<br/><font class="lozenge">◊</font> If a moderate- or high-risk procedure was bloody, then a 24-hour interval should be observed.<br/>§ After an intervention, the usual daily dose (75 mg) of clopidogrel can be started 12 hours later. If a loading dose of clopidogrel is given, then the interval should be 24 hours.<br/>¥ For more information, refer to the section entitled "SRIs and Anticoagulants" and table 6 in the source article, as well as the UpToDate content on the pharmacology and side effects of selective serotonin reuptake inhibitors.</div><div class="graphic_reference">Reproduced with permission from: Narouze S, Benzon HT, Provenzano DA, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulation medications (second edition): Guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med 2018; 43(3):225-262. Copyright © 2018 BMJ Publishing Group Ltd.</div><div id="graphicVersion">Graphic 108918 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
